• CSPC Pharmaceutical Group announced on Nov. 3, 2026, the initiation of its Phase II SYH2072 hypertension trial at China's first participating center.
• The placebo-controlled study will evaluate efficacy and safety in uncontrolled hypertension, including resistant hypertension, despite treatment with two or more antihypertensive medications.
• SYH2072 is an aldosterone synthase inhibitor designed to lower blood pressure by reducing aldosterone production.
• Preliminary Phase I findings supported the drug's safety profile; Chinese regulators cleared clinical testing in December 2025.
• Participant recruitment and screening are underway for the multicenter, randomized, double-blind trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261103-12397743), on November 03, 2026, and is solely responsible for the information contained therein.